Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. The Hunt for the Next 10 Bagger Message Board

Gold miners, biotech among worst-performing ETFs d

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 102810
Posted On: 10/15/2013 9:21:12 PM
Avatar
Posted By: ruliquid

Gold miners , biotech among worst-performing ETFs during shutdown
The Market Vectors Junior Gold Miners ETF GDXJ is so far the biggest loser among ETFs during the U.S. government shutdown.


Its 14.2% loss since Oct. 1 makes it the worst-performing U.S. ETF, excluding leveraged products. That’s according to Morningstar data as of Monday’s close.


Related ETFs — the Global X Gold Explorers ETF GLDX and the Market Vectors Gold Miners ETF GDX 0.13% — are not too far behind GDXJ with month-to-date drops of 10.3% and 8%. The SPDR Gold Trust GLD has also been lagging with a 3.1% slide over the same period — making it among the 100 worst-performing U.S. ETFs, according to the Morningstar data.


You might think gold-related plays would have fared better during the shutdown given their safe-haven reputation. But one headwind has been several big banks cutting their forecasts for gold prices. Still, analysts have described gold as “broken” for its failure to respond to what should be good news for that commodity.


Biotech ETFs also have been big losers so far during the shutdown, with several among the 100 worst-performing ETFs. The SPDR S&P Biotech ETF XBI has lost 7.2%, the Market Vectors Biotech ETF BBH is down 5.2% and the iShares Nasdaq Biotech ETF IBB has slipped 3.4%.


MarketWatch columnist Kevin Marder has suggested this is a sign of speculative sentiment receding. Barron’s Brendan Conway reports that a significant percentage of investors view biotech as overvalued after the sector’s strong gains this year.


So with biotech and gold miners, it appears the shutdown is not the main driver of their performance so far in October. Instead, it’s the other factors mentioned. http://blogs.marketwatch.com/thetell/2013/10/...-shutdown/



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us